Cambinol, a non-competitive nSMase2 inhibitor, hinders exosome-mediated tau protein transfer between cells and the spread of pathological forms of tau protein between cells by inhibiting nSMase2 activity, thereby slowing down the progression of AD (Zhu et al., 2021). Here, MAPT is linked to Alzheimer disease.